Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v2.4.0.8
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
Jun. 30, 2014
Dec. 31, 2013
Current assets    
Cash      
Total current assets      
Equipment - net 842 1,230
Total Assets 842 1,230
Current liabilities    
Accounts payable 584,163 421,597
Accrued interest payable 331,944 268,950
Notes payable - current -non related parties 573,516 573,516
Notes payable - current, net 645,518 612,342
Derivative liability 121,757 150,067
Stock subscription payable - current 28,067 26,000
Related party payables 250,765 190,765
Other payables 241,225 238,085
Total current liabilities 2,776,955 2,481,322
Notes payable - non related parties 167,007 167,007
Total Liabilities 2,943,962 2,648,329
Stockholders' Deficit    
Common stock, $.00001 par value; 100,000,000 shares authorized; 39,098,081 and 34,146,712 shares issued and outstanding at June 30, 2014 and December 31, 2013 respectively 392 342
Additional paid in capital 12,530,457 12,415,639
Deficit accumulated during the development stage (15,441,182) (15,032,660)
Total Transbiotec, Inc. stockholders' deficit (2,910,333) (2,616,679)
Noncontrolling interest (32,787) (30,420)
Total Stockholders' Deficit (2,943,120) (2,647,099)
Total Liabilities and Stockholders' Deficit $ 842 $ 1,230